WednesdayFeb 18, 2026 10:00 am

Pressure from Brain Tumors Triggers Self-Destruct Mechanism in Neurons, Study Finds

Brain tumors may damage surrounding tissue in a more insidious way than previously understood. New research from the University of Notre Dame shows that chronic pressure from an expanding tumor does not simply crush nearby neurons. It activates an internal self-destruction program that pushes those cells toward death.  Neurons form the backbone of thought, movement and sensation. When they die, the brain cannot easily replace them. That loss often leads to cognitive decline, motor impairment and sensory deficits seen in patients with aggressive brain cancers and traumatic injuries.  An interdisciplinary team at the University of Notre Dame set out to examine how mechanical compression alone affects healthy brain cells. Meenal Datta, a professor of aerospace and mechanical engineering…

Continue Reading

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

Continue Reading

TuesdayFeb 17, 2026 10:00 am

Existing Cancer Drug Shows Potential in Reactivating Immunotherapy

An already approved cancer drug called Carfilzomib may help restore the effectiveness of CAR-T cell therapy in advanced multiple myeloma cases. Technical University of Munich researchers have discovered a molecular mechanism that causes cancer cells to evade treatment and have shown that blocking it can make immunotherapy work again in some patients.  CAR-T cell therapy involves removing a patient's T cells, genetically altering them in the laboratory, and reintroducing them so they can recognize and attack cancer cells. For multiple myeloma, these engineered cells target a molecule known as BCMA, which appears on diseased plasma cells. The approach can extend survival, sometimes by years,…

Continue Reading

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its…

Continue Reading

WednesdayFeb 11, 2026 10:00 am

New AI Model Predicts Dementia Risk, Cancer Survival and Brain Age

Mass General Brigham researchers have developed a new AI model that can estimate brain age, assess a patient’s risk of developing dementia, and help predict survival outcomes for brain cancer using routine MRI scans. The system, created within the Harvard-affiliated health network, is designed to pull multiple clinical signals from a single brain image rather than being trained for one narrow diagnostic task.  Known as BrainIAC, the model takes a different approach from most medical AI tools currently in use. Instead of relying on massive, carefully labeled datasets tied to one disease or outcome, BrainIAC is built to adapt across a range of neurological and oncology-related problems. Researchers say that…

Continue Reading

MondayFeb 09, 2026 10:00 am

Investors React Positively to Meta’s Plan to Increase AI Capex

Investors are responding positively to Meta’s decision to keep increasing artificial intelligence spending, even as fears grow that the AI boom could be inflating a bubble. While concerns about a potential bust are becoming more common, Meta’s latest earnings suggest that, for now, the market is still willing to back heavy investment, particularly when it produces clear financial results.  Those fears are not unfounded. A growing share of AI spending is circular in nature, and the circular investment nature among companies involved in AI has raised concerns about artificial demand propping up valuations. Large tech companies are buying chips, cloud capacity, and services from the same small group of firms…

Continue Reading

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s…

Continue Reading

WednesdayFeb 04, 2026 11:15 am

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them Multiple active trials across ovarian clear cell cancer, colon cancer, and soft tissue sarcoma support a platform approach Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well…

Continue Reading

WednesdayFeb 04, 2026 10:00 am

Scientists Discover Why Immunotherapy Frequently Fails

Although cancer immunotherapy has transformed treatment for many patients, the promise of effective immunotherapy falls short for many patients. Scientists now believe they have identified a major reason why immunotherapy isn't always effective.  New research shows that cancer cells rely on a previously hidden escape route to weaken immune attacks, and a class of widely used medications may help block it. The study, led by Professor Kunihiro Tsuchida at Fujita Health University, suggests that cancer cells do more than evade immune checkpoints.  They actively distribute immune-suppressing signals throughout the body, reducing the effectiveness of immunotherapy even when tumors appear responsive based on standard markers.  Immunotherapy drugs such as PD-1 and PD-L1 inhibitors work by releasing the…

Continue Reading

WednesdayFeb 04, 2026 9:45 am

GridAI Technologies Corp. (NASDAQ: GRDX) Targeting Energy Control Bottleneck Facing AI Data Centers

Power availability and control are emerging as binding constraints on AI data center growth, with efficient energy control now seen as critical to the financial viability of hyperscale AI campuses. GridAI focuses its AI-native software on energy orchestration rather than power generation or hardware, operating at the intersection of utilities, power markets, and large AI-driven electricity demand. The company’s technology manages energy flows outside the data center, across grid assets, storage, and on-site generation. For much of the past decade, the investment narrative around artificial intelligence has revolved around semiconductors, cloud platforms, and talent. More recently, attention has shifted to…

Continue Reading

Contact us: (512) 354-7000